These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17366681)

  • 21. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
    Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
    Ding L; Liu K; Jiang Z; Chen Q; Zhou N; Liang Y; Gao H; Hong X; Wu H
    Tumour Biol; 2015 Apr; 36(4):2491-9. PubMed ID: 25417899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Long-term survival of patient with brain metastases from lung cancer treated by pemetrexed monotherapy].
    Ito S; Ogawa Y; Harada H; Yamaguchi T; Munakata K
    Gan To Kagaku Ryoho; 2012 May; 39(5):793-6. PubMed ID: 22584333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.
    Zinner RG; Fossella FV; Gladish GW; Glisson BS; Blumenschein GR; Papadimitrakopoulou VA; Pisters KM; Kim ES; Oh YW; Peeples BO; Ye Z; Curiel RE; Obasaju CK; Hong WK; Herbst RS
    Cancer; 2005 Dec; 104(11):2449-56. PubMed ID: 16258975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pemetrexed-induced anaphylaxis.
    Shah BK; Hewett Y
    Acta Oncol; 2013 May; 52(4):881. PubMed ID: 23472834
    [No Abstract]   [Full Text] [Related]  

  • 27. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study.
    Jalal S; Ansari R; Govindan R; Bhatia S; Bruetman D; Fisher W; Masters G; White A; Stover D; Yu M; Hanna N;
    J Thorac Oncol; 2009 Jan; 4(1):93-6. PubMed ID: 19096313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
    Ciuleanu T; Brodowicz T; Zielinski C; Kim JH; Krzakowski M; Laack E; Wu YL; Bover I; Begbie S; Tzekova V; Cucevic B; Pereira JR; Yang SH; Madhavan J; Sugarman KP; Peterson P; John WJ; Krejcy K; Belani CP
    Lancet; 2009 Oct; 374(9699):1432-40. PubMed ID: 19767093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV; Felip E; Besse B; von Pawel J; Mellemgaard A; Reck M; Bosquee L; Chouaid C; Lianes-Barragán P; Paul EM; Ruiz-Soto R; Sigal E; Ottesen LH; Lechevalier T
    J Thorac Oncol; 2013 Dec; 8(12):1529-37. PubMed ID: 24389434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
    Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
    Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
    Hainsworth JD; Cebotaru CL; Kanarev V; Ciuleanu TE; Damyanov D; Stella P; Ganchev H; Pover G; Morris C; Tzekova V
    J Thorac Oncol; 2010 Oct; 5(10):1630-6. PubMed ID: 20802351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
    Stevenson JP; Langer CJ; Somer RA; Evans TL; Rajagopalan K; Krieger K; Jacobs-Small M; Dyanick N; Milcarek B; Coakley S; Walker S; Eaby-Sandy B; Hageboutros A
    Cancer; 2012 Nov; 118(22):5580-7. PubMed ID: 22544579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Eisenhauer E; Butts C; Gregg R; Dancey J; Fisher B; Iglesias J
    J Clin Oncol; 1999 Apr; 17(4):1194. PubMed ID: 10561178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pemetrexed for treatment of advanced non-small cell lung cancer.
    Fossella FV
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):100-5. PubMed ID: 14981587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: an open-label single-arm study.
    Chang GC; Tsai CM; Hsia TC; Yang CH; Abdulnabi R; Blair JM; Linn C
    J Formos Med Assoc; 2013 Sep; 112(9):518-26. PubMed ID: 24060197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asteatotic eczema ('eczema craquelé') with histopathological interface dermatitis: a new cutaneous reaction following pemetrexed.
    Frouin E; Sebille G; Freudenberger S; Menecier B; Quoix E; Cribier B; Lipsker D
    Br J Dermatol; 2012 Jun; 166(6):1359-60. PubMed ID: 22182200
    [No Abstract]   [Full Text] [Related]  

  • 40. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
    Socinski MA; Raju RN; Neubauer M; Smith DA; Richards DA; Savin M; Ruxer RL; Reynolds CH; Zhan F; Bromund JL; Chen R; Obasaju C
    J Thorac Oncol; 2008 Nov; 3(11):1308-16. PubMed ID: 18978567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.